MILAN (AIMnews.it) - A clinical study conducted at the Umberto I Hospital in Rome, which focused on the effects of Kolinpharma's Xinepa supplement, demonstrated the efficacy of the nutraceutical product for the treatment of peripheral neuropathies. The results of this study will be published in the journal The Journal of Physical Therapy Science. "This study also confirms the peculiarity of the Kolnpharma approach, which stands out in the nutraceutical market for the constant research of scientific evidence demonstrating the effectiveness of our products based on active ingredients" - said President Rita Paola Petrelli. Carpal tunnel syndrome affects 7-8% of the European population over 55 and the market for musculoskeletal care products, in which peripheral neuropathies fall, according to Federsalus data, is equal to 125 in Italy, 3 million euros and estimated to grow by 5% compared to 2016.